Press release
Generalized Anxiety Disorder Market Set to Grow Substantially Through 2034, DelveInsight Projects | Fabre-Kramer Pharma, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories
DelveInsight's "Generalized Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Generalized Anxiety Disorder, historical and forecasted epidemiology as well as the Generalized Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.To Know in detail about the Generalized Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Generalized Anxiety Disorder Market Forecast
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Generalized Anxiety Disorder Market Report:
• The Generalized Anxiety Disorder market size was valued approximately USD 1,560 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2024, Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company focused on advancing both traditional and innovative behavioral health treatments with a strong emphasis on safe, evidence-based novel therapies, extends its congratulations to Mind Medicine ("MindMed" NASDAQ: MNMD, Cboe Canada: MMED) for the positive outcomes from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for treating generalized anxiety disorder ("GAD"). The study revealed that four weeks after a single 100-microgram dose of MM120, 48 percent of participants achieved remission, no longer exhibiting clinically significant anxiety, while 65 percent experienced a clinically meaningful improvement. Due to the promising initial clinical data from the Phase 2b trial and the considerable unmet medical need in treating GAD, the U.S. Food & Drug Administration ("FDA") has granted MM120 breakthrough therapy designation for GAD.
• In 2023, the EU4 and the UK generated an estimated USD 472 million, with expectations for significant growth at a strong compound annual growth rate (CAGR). Among the European countries, Germany held the largest market share, followed by Italy and Spain.
• In 2023, approximately 8.77 million individuals in the United States were diagnosed with Generalized Anxiety Disorder (GAD), with this number projected to grow at a steady compound annual growth rate (CAGR) during the study period from 2020 to 2034.
• In 2023, Germany recorded the highest diagnosed prevalence of Generalized Anxiety Disorder (GAD) among the EU4 and the UK, with approximately 1.46 million cases, followed by Italy and Spain. Conversely, the UK had the lowest number of diagnosed cases within the European region that year.
• Japan recorded an estimated 1.36 million diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) in 2023.
• According to DelveInsight's analysis, the diagnosed prevalent cases of Generalized Anxiety Disorder (GAD) were classified into four age groups: 18-29 years, 30-44 years, 45-59 years, and 60 years and older.
• Key Generalized Anxiety Disorder Companies: VistaGen Therapeutics, Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
• Key Generalized Anxiety Disorder Therapies: Fasedienol (PH94B), EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
• The Generalized Anxiety Disorder epidemiology based on gender analyzed that Generalized anxiety disorder (GAD) is more prevalent in females than males
• The Generalized Anxiety Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Generalized Anxiety Disorder pipeline products will significantly revolutionize the Generalized Anxiety Disorder market dynamics.
Generalized Anxiety Disorder Overview
The most prevalent anxiety illness in primary care is generalised anxiety disorder (GAD), which has a high degree of comorbidity, impairment, and disability. GAD is characterised by a waxing and waning course, frequently without complete remission, and a pattern of persistent, chronic worry, anxious symptoms, and tension.
Get a Free sample for the Generalized Anxiety Disorder Market Report:
https://www.delveinsight.com/report-store/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Generalized Anxiety Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Generalized Anxiety Disorder Epidemiology Segmentation:
The Generalized Anxiety Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Generalized Anxiety Disorder
• Prevalent Cases of Generalized Anxiety Disorder by severity
• Gender-specific Prevalence of Generalized Anxiety Disorder
• Diagnosed Cases of Episodic and Chronic Generalized Anxiety Disorder
Download the report to understand which factors are driving Generalized Anxiety Disorder epidemiology trends @ Generalized Anxiety Disorder Epidemiology Forecast
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Generalized Anxiety Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Anxiety Disorder market or expected to get launched during the study period. The analysis covers Generalized Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Generalized Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Generalized Anxiety Disorder Therapies and Key Companies
• Fasedienol (PH94B): VistaGen Therapeutics
• EXXUA: Fabre-Kramer Pharmaceuticals
• MM-120: Mind Med
• Ulotaront(SEP363856): Sunovion
• CD-008-0045: ChemRar Research
• Troriluzole: Biohaven Pharma
• Vilazodone: Forest Laboratories
• SEP-363856: Sumitomo Pharma
• Duloxetine: Eli Lilly and Company
• ENX-102: Engrail Therapeutics INC
• Escitalopram: H. Lundbeck A/S
• Vortioxetine: Takeda
• eszopiclone: Sumitomo Pharma
• Lu AA21004: H. Lundbeck A/S
• Quetiapine fumarate: Astrazeneca
• Sensoril®: Natreon, Inc.
• Pregabalin: Pfizer
• pexacerfont: Bristol-Myers Squibb
Discover more about therapies set to grab major Generalized Anxiety Disorder market share @ Generalized Anxiety Disorder Treatment Market
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Generalized Anxiety Disorder Market Strengths
• A series of diagnostic guidelines, each building on the prior, have presented clear diagnostic criteria and led to a standardization of reporting in the field, increasing the diagnostic and treatment rate.
• Increased diagnosis rates in various countries is directly associated with the growing geriatric population and fast-paced lifestyle among adults.
• Research examining novel pharmacotherapies and refining psychosocial approaches for the treatment of GAD is underway and promises to provide additional treatment
Generalized Anxiety Disorder Market Opportunities
• There is an urgent requirement for therapies that are safer and have rapid action.
• Despite the significant unmet needs in the treatment, only a few players are actively involved in the therapy area, thus, the market offers opportunities to players to bring novel treatments that could shift the treatment paradigm
• Epidemiologic studies may help in planning treatment and prevention programs, and may also help us better understand the etiology of these disorders.
Scope of the Generalized Anxiety Disorder Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Generalized Anxiety Disorder Companies: VistaGen Therapeutics, Fabre-Kramer Pharmaceuticals, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories, Sumitomo Pharma, Eli Lilly and Company, Engrail Therapeutics INC, H. Lundbeck A/S, Takeda, Sumitomo Pharma, Astrazeneca, Natreon, Inc., Pfizer, Bristol-Myers Squibb, and others
• Key Generalized Anxiety Disorder Therapies: Fasedienol (PH94B), EXXUA, MM-120, Ulotaront(SEP363856), CD-008-0045, Troriluzole, Vilazodone, SEP-363856, Duloxetine, ENX-102, Escitalopram, Vortioxetine, eszopiclone, Lu AA21004, Quetiapine fumarate, Sensoril®, Pregabalin, pexacerfont, and others
• Generalized Anxiety Disorder Therapeutic Assessment: Generalized Anxiety Disorder current marketed and Generalized Anxiety Disorder emerging therapies
• Generalized Anxiety Disorder Market Dynamics: Generalized Anxiety Disorder market drivers and Generalized Anxiety Disorder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Generalized Anxiety Disorder Unmet Needs, KOL's views, Analyst's views, Generalized Anxiety Disorder Market Access and Reimbursement
To know more about Generalized Anxiety Disorder companies working in the treatment market, visit @ Generalized Anxiety Disorder Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/generalized-anxiety-disorder-gad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Generalized Anxiety Disorder Market Report Introduction
2. Executive Summary for Generalized Anxiety Disorder
3. SWOT analysis of Generalized Anxiety Disorder
4. Generalized Anxiety Disorder Patient Share (%) Overview at a Glance
5. Generalized Anxiety Disorder Market Overview at a Glance
6. Generalized Anxiety Disorder Disease Background and Overview
7. Generalized Anxiety Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Generalized Anxiety Disorder
9. Generalized Anxiety Disorder Current Treatment and Medical Practices
10. Generalized Anxiety Disorder Unmet Needs
11. Generalized Anxiety Disorder Emerging Therapies
12. Generalized Anxiety Disorder Market Outlook
13. Country-Wise Generalized Anxiety Disorder Market Analysis (2020-2034)
14. Generalized Anxiety Disorder Market Access and Reimbursement of Therapies
15. Generalized Anxiety Disorder Market Drivers
16. Generalized Anxiety Disorder Market Barriers
17. Generalized Anxiety Disorder Appendix
18. Generalized Anxiety Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Generalized Anxiety Disorder Pipeline https://www.delveinsight.com/report-store/generalized-anxiety-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Generalized Anxiety Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Generalized Anxiety Disorder market. A detailed picture of the Generalized Anxiety Disorder pipeline landscape is provided, which includes the disease overview and Generalized Anxiety Disorder treatment guidelines.
Generalized Anxiety Disorder Epidemiology https://www.delveinsight.com/report-store/generalized-anxiety-disorder-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Generalized Anxiety Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Generalized Anxiety Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Generalized Anxiety Disorder Market Set to Grow Substantially Through 2034, DelveInsight Projects | Fabre-Kramer Pharma, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Laboratories here
News-ID: 3791612 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Generalized
Key Trends Influencing the Growth of the Generalized Anxiety Disorder Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Generalized Anxiety Disorder Market Through 2025?
In recent years, there has been a consistent expansion in the market size for generalized anxiety disorder. The market, which is predicted to grow from $7.76 billion in 2024 to $8.01 billion in 2025, will experience…
Rising Mental Disorder Cases Drive Expansion Of The Generalized Anxiety Disorder …
The Generalized Anxiety Disorder Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Generalized Anxiety Disorder Market Size and Projected Growth Rate?
The market size for generalized anxiety disorder has seen a stable growth in the past few years. The market is expected to…
Key Generalized Anxiety Disorder Market Trend for 2025-2034: Innovative Drug Dev …
"What Is the Future Outlook for the Generalized Anxiety Disorder Market's Size and Growth Rate?
The generalized anxiety disorder market will grow from $7.76 billion in 2024 to $8.01 billion in 2025, at a CAGR of 3.2%. Growth is driven by increased mental health awareness, pharmaceutical advances, the popularity of cognitive-behavioral therapy (CBT), and the stressful lifestyle changes of modern society.
The generalized anxiety disorder market is expected to reach $9.32 billion…
Global Generalized Anxiety Disorder Treatment Market Imapct of AI and Automation
Generalized Anxiety Disorder Treatment Market Impact of AI and Automation
The Generalized Anxiety Disorder (GAD) treatment market has been experiencing significant growth due to the increasing prevalence of anxiety disorders globally, rising awareness about mental health, and the development of advanced therapeutic options. In 2022, the market size was valued at approximately USD 7.5 billion and is expected to grow at a compound annual growth rate (CAGR) of around 6.5% from…
Generalized Anxiety Disorder Market Report and Forecast 2024-2032
Generalized Anxiety Disorder Market Outlook
The generalized anxiety disorder market size in the 7 major markets was valued at USD 1717.5 million in 2023, driven by the increasing advancements in psychotherapeutic as well as pharmacological treatment options for patients. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to rise from USD 1809.8 million in 2024 to USD 2751.1…
Generalized Anxiety Disorder Pipeline Insight Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Generalized Anxiety Disorder Pipeline constitutes 10+ key companies continuously working towards developing 12+ Generalized Anxiety Disorder Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Generalized Anxiety Disorder Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Generalized…